feedback

Course Director

Prof. Jürgen C. Becker, MD, PhD
Prof. Jürgen C. Becker, MD, PhD

German Consortium for Translational Cancer Research - DKTK
University Hospital Essen
​University Duisburg-Essen​
Essen, Germany​

Faculty

Sunandana Chandra
Sunandana Chandra, MD, MS

Northwestern University Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois

Guilherme Rabinowits
Guilherme Rabinowits, MD

Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Geoffrey T. Gibney
Geoffrey T. Gibney, MD

Lombardi Comprehensive Cancer Center
MedStar Georgetown University Hospital
Washington, DC

Accredited by

Rutgers Biomedical and Health Sciences

Activity Details

Credit Types:CME / CNE
Credit Amount:2.0 Credits
Release Date:2017-May-15
Expiration Date:2018-May-14
Estimated Time for Completion:120 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

Anti-cancer immunotherapy is showing remarkable promise in Merkel cell carcinoma (MCC) and is expected to become the new backbone of therapy for patients with these aggressive skin cancers who previously had very limited treatment options. During this Progress-in-Practice Master Class, experts discussed the key etiologic factors, oncogenic mechanisms, and immunogenicity of MCC, as well as data from clinical trials assessing immune-based treatment approaches and practicalities related to their use in MCC. The current state of the science and future research directions related to biomarkers, novel immune targets, and various combination strategies in MCC and beyond—including other virus-associated cancers—was also explored.

Upon completion of this activity, participants will be able to:

  • Characterize the risks and causative factors underlying the development of different subtypes of MCC, including the role of the oncogenic Merkel cell polyomavirus and UV light as a carcinogen, as well as the documented and putative mechanisms of tumorigenesis and immune evasion
  • Describe the rationale for use and mechanisms of action of various localized and systemic immune-based treatment approaches under investigation for MCC
  • Summarize the efficacy and safety data from latest clinical trials assessing novel immunotherapies for MCC, including anti–PD-1 and anti–PD-L1 immune checkpoint blockade therapies
  • Discuss forward-looking research directions involving immunotherapy in MCC and beyond, including biomarker development, assessment of rational immunotherapy-based combination strategies and other novel immune targets, and the feasibility of targeting other oncogenic virus-associated tumors with immune-mediated therapies
  • Recognize and diagnose MCC accurately and in a timely manner
  • Recommend immunotherapy to appropriate patients with MCC and monitor these patients adequately to assess response to therapy as well as detect and manage potential immune-related adverse effects

Target Audience

This activity is intended for medical oncologists, dermatologists, skin cancer specialists, surgeons, nurses, and other healthcare professionals engaged in the care of patients with MCC.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: May 15, 2017 - May 14, 2018
Time to Complete: 120 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with the disclosure policies of Rutgers Biomedical and Health Sciences and to conform with Joint Accreditation requirements and FDA guidelines, individuals in a position to control the content of this educational activity are required to disclose to the activity participants: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.

Course Director and Moderator

Prof. Jürgen C. Becker, MD, PhD
Translational Skin Cancer Research
Department Head
German Consortium for Translational Cancer Research - DKTK
University Hospital Essen
Biological Faculty (coop)
University Duisburg-Essen
Essen, Germany

Prof. Jürgen C. Becker, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Bristol-Myers Squibb and Merck Serono.
Speakers Bureau participant with Amgen Inc.; Merck Serono; and Pfizer Inc.
Advisory Board for Amgen Inc.; Merck Serono; Novartis; Pfizer Inc.; and Takeda Pharmaceutical Company Limited.

Faculty

Sunandana Chandra, MD, MS
Assistant Professor, Division of Hematology Oncology
Northwestern University Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois

Sunandana Chandra, MD, MS, has a financial interest/relationship or affiliation in the form of:
Advisory Board for Bristol-Myers Squibb and EMD Serono, Inc.

Guilherme Rabinowits, MD
Medical Oncology
Instructor in Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Center for Head and Neck Oncology
Boston, Massachusetts

Guilherme Rabinowits, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for EMD Serono, Inc.
Grant/Research Support from EMD Serono, Inc.; Exelixis, Inc.; and Millennium Pharmaceuticals, Inc. (all support goes to institution).
Advisory Board for EMD Serono, Inc.

Geoffrey T. Gibney, MD
Co-Leader, Melanoma Disease Group
Lombardi Comprehensive Cancer Center
MedStar Georgetown University Hospital
Washington, DC

Geoffrey T. Gibney, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Genentech, Inc. and Novartis Pharmaceuticals Corporation.
Speakers Bureau participant with Genentech, Inc. and Merck & Co., Inc.

Peer Reviewer

Phaedra Kirin, RN, BSN, OCN
Research Nurse Clinician
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey

Phaedra Kirin, RN, BSN, OCN, has no financial interests/relationships or affiliations in relation to this activity.

Accredited Provider

Elizabeth S. Ward, MSJ
Executive Director
Center for Continuing and Outreach Education
Rutgers, The State University of New Jersey
Newark, New Jersey

Elizabeth S. Ward, MSJ, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.

In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, RBHS has resolved all potential and real conflicts of interest through content review by a non-conflicted, qualified reviewer. This activity was peer-reviewed for relevance, accuracy of content and balance of presentation by Phaedra Kirin, RN, BSN, OCN.

This activity was pilot-tested for time required for participation by Heather Camisa, RN, BSN, Joshua Kra, MD, Jennifer Lee, BSN, and Kristen Spencer, DO, MPH. The pilot testers have no relevant financial relationships to disclose.

Providership, Credit & Support

In support of improving patient care, this activity has been planned and implemented by Rutgers Biomedical and Health Sciences and PVI, PeerView Institute for Medical Education. Rutgers Biomedical and Health Sciences is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

Rutgers Biomedical and Health Sciences designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

This activity is awarded 2.0 contact hours.

Providership

This CME/CNE activity is jointly provided by Rutgers Biomedical and Health Sciences and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an educational grant from Pfizer and EMD Serono.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2017, PeerView Press - Medical Education Resource

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.